- Report
- March 2025
- 150 Pages
Global
From €5418EUR$5,950USD£4,660GBP
- Report
- February 2025
- 200 Pages
Global
From €4089EUR$4,490USD£3,516GBP
- Report
- April 2025
- 175 Pages
Global
From €4089EUR$4,490USD£3,516GBP
- Report
- May 2024
- 130 Pages
Global
From €5918EUR$6,499USD£5,090GBP
- Report
- August 2024
- 150 Pages
Global
From €2540EUR$2,789USD£2,184GBP
- Report
- November 2019
- 150 Pages
Global
From €1252EUR$1,375USD£1,077GBP
€2504EUR$2,750USD£2,154GBP
- Report
- April 2021
China
From €2368EUR$2,600USD£2,036GBP
From €3187EUR$3,500USD£2,741GBP
- Report
- January 2025
- 85 Pages
Saudi Arabia
From €3187EUR$3,500USD£2,741GBP
- Report
- November 2023
- 276 Pages
Global
From €8651EUR$9,500USD£7,440GBP
- Report
- April 2023
- 120 Pages
Global
From €4326EUR$4,750USD£3,720GBP
- Drug Pipelines
- December 2022
- 30 Pages
Global
From €2960EUR$3,250USD£2,545GBP
- Report
- January 2022
- 125 Pages
Global
From €1821EUR$2,000USD£1,566GBP
- Report
- January 2022
- 125 Pages
Global
From €2277EUR$2,500USD£1,958GBP
- Report
- October 2023
- 73 Pages
United States
From €3187EUR$3,500USD£2,741GBP
- Report
- January 2023
- 116 Pages
Global
From €4098EUR$4,500USD£3,524GBP
- Report
- September 2021
- 152 Pages
Global
From €13656EUR$14,995USD£11,744GBP
- Report
- May 2023
- 96 Pages
Global
From €3500EUR$4,117USD£3,115GBP
- Report
- January 2025
- 93 Pages
Global
From €3500EUR$4,117USD£3,115GBP

Herceptin is a monoclonal antibody used to treat certain types of breast and gastric cancer. It is also used in the treatment of non-small cell lung cancer (NSCLC). Herceptin works by targeting the HER2 protein, which is found in higher levels in some types of cancer cells. This helps to slow down or stop the growth of cancer cells. Herceptin is used in combination with chemotherapy and other drugs to treat NSCLC.
Herceptin is a relatively new drug in the lung cancer market, but it has been shown to be effective in treating certain types of NSCLC. It is generally well-tolerated and has fewer side effects than other treatments. Herceptin is also used in combination with other drugs to treat metastatic NSCLC, which is when the cancer has spread to other parts of the body.
Herceptin is available in both generic and brand-name versions. It is typically administered intravenously in a hospital or clinic setting.
Some companies in the Herceptin market include Genentech, Roche, Merck, and Pfizer. Show Less Read more